Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Pancreatic Adenocarcinoma, Version 2.2012 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Tempero, M. A., Arnoletti, J. P., Behrman, S. W., Ben-Josef, E., Benson, A. B., Casper, E. S., Cohen, S. J., Czito, B., Ellenhorn, J. D., Hawkins, W. G., Herman, J., Hoffman, J. P., Ko, A., Komanduri, S., Koong, A., Ma, W. W., Malafa, M. P., Merchant, N. B., Mulvihill, S. J., Muscarella, P., Nakakura, E. K., Obando, J., Pitman, M. B., Sasson, A. R., Tally, A., Thayer, S. R., Whiting, S., Wolff, R. A., Wolpin, B. M., Freedman-Cass, D. A., Shead, D. A. 2012; 10 (6): 703-713

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

View details for Web of Science ID 000304889700004

View details for PubMedID 22679115